Company intelligence / Profile preview

Amalgent Therapeutics

Greenville, North Carolina, United Statesamalgent.com ↗

Ownership: Private
Development stage: Clinical

Overview

Amalgent has advanced a novel oral fixed-dose combination therapy for pain management into early clinical trials. The approach repurposes existing drugs to improve safety and efficacy over traditional opioids. Proof-of-concept data and preclinical work have enabled rapid progression toward commercialization. Early results suggest the therapy may also protect against nervous system injury consequences.[2]

Therapeutic areas: Neurology
Modalities: Small moleculesfixed-dose combination drugs[3][8]
Industry: Biotech

Drug pipeline

2 assets

AMGT-0230

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

East Carolina University (technology licensing/collaboration)[1][4]National Institute on Drug Abuse/National Institutes of Health SBIR funding partner for clinical development grants ($2M+ awarded)[2]Ongoing academic collaboration with Dr. Kori Brewer & Dr. Stefan Clemens at ECU for preclinical addiction studies as part of the project.[4]No major pharmaceutical partnerships publicly listed as of May 2025.

Beyond the preview

Go deeper on Amalgent Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amalgent Therapeutics.

Explore the full profile